Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: A Southwest Oncology Group study

S. H. Petersdorf, K. J. Kopecky, D. R. Head, D. H. Boldt, S. P. Balcerzak, T. Wun, Vivek Roy, R. W. Veith, F. R. Appelbaum

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The effectiveness of intensive post-remission chemotherapy regimens for adult patients with acute lymphoblastic leukemia (ALL) is limited by both a high rate of disease recurrence and a substantial incidence of treatment toxicity. To evaluate a potentially more effective and less toxic approach, we conducted a multicenter phase III trial of consolidation therapies comparing the standard L10M regimen with one combining the brief, intensive L17M regimen and escalating methotrexate (MTX) and L-asparaginase (L-asp). Patients over age 15 with previously untreated ALL were eligible. Induction therapy included vincristine, prednisone, doxorubicin, cyclophosphamide and intrathecal methotrexate administered over 36 days. Patients who achieved complete remission (CR) were randomized to receive consolidation with either the L10M regimen or with DAT (daunomycin, cytosine arabinoside, 6-thioguanine) and escalating MTX and L-asp. The randomization was stratified by age, WBC and Ph chromosome status. Maintenance therapy was the same in both arms. Of 353 eligible patients, 218 (62%) achieved CR and 195 were randomized. The treatment arms did not differ significantly with respect to disease-free survival (DFS; P=0.46) or overall survival (P=0.39). Estimated DFS at 5 years was 32% (95% confidence interval (CI) 23-42%) in the L10M arm and 25% (95% CI 16-33%) in the DAT/MTX/L-asp arm. In each arm, 4% of patients died of toxicities (infection in all but one case). Infections and nausea/vomiting were somewhat more common in the L10M arm (occurring in 68% and 53% of patients respectively) than the DAT/MTX/L-asp arm (56% and 33%). The DAT/MTX/L-asp consolidation regimen was associated with some reduction in nonfatal toxicities, but no significant improvement in DFS, overall survival or non-relapse mortality when compared to the standard L10M regimen.

Original languageEnglish (US)
Pages (from-to)208-216
Number of pages9
JournalLeukemia
Volume15
Issue number2
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Asparaginase
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methotrexate
Thioguanine
Daunorubicin
Cytarabine
Confidence Intervals
Therapeutics
Survival
Poisons
Vincristine
Random Allocation
Prednisone
Infection
Doxorubicin
Cyclophosphamide
Nausea
Disease-Free Survival
Vomiting
Chromosomes

Keywords

  • Acute lymphoblastic leukemia
  • Consolidation
  • Randomized

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia : A Southwest Oncology Group study. / Petersdorf, S. H.; Kopecky, K. J.; Head, D. R.; Boldt, D. H.; Balcerzak, S. P.; Wun, T.; Roy, Vivek; Veith, R. W.; Appelbaum, F. R.

In: Leukemia, Vol. 15, No. 2, 01.01.2001, p. 208-216.

Research output: Contribution to journalArticle

Petersdorf, S. H. ; Kopecky, K. J. ; Head, D. R. ; Boldt, D. H. ; Balcerzak, S. P. ; Wun, T. ; Roy, Vivek ; Veith, R. W. ; Appelbaum, F. R. / Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia : A Southwest Oncology Group study. In: Leukemia. 2001 ; Vol. 15, No. 2. pp. 208-216.
@article{b1c3e6f56e224922a46ca5a2a8e35481,
title = "Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: A Southwest Oncology Group study",
abstract = "The effectiveness of intensive post-remission chemotherapy regimens for adult patients with acute lymphoblastic leukemia (ALL) is limited by both a high rate of disease recurrence and a substantial incidence of treatment toxicity. To evaluate a potentially more effective and less toxic approach, we conducted a multicenter phase III trial of consolidation therapies comparing the standard L10M regimen with one combining the brief, intensive L17M regimen and escalating methotrexate (MTX) and L-asparaginase (L-asp). Patients over age 15 with previously untreated ALL were eligible. Induction therapy included vincristine, prednisone, doxorubicin, cyclophosphamide and intrathecal methotrexate administered over 36 days. Patients who achieved complete remission (CR) were randomized to receive consolidation with either the L10M regimen or with DAT (daunomycin, cytosine arabinoside, 6-thioguanine) and escalating MTX and L-asp. The randomization was stratified by age, WBC and Ph chromosome status. Maintenance therapy was the same in both arms. Of 353 eligible patients, 218 (62{\%}) achieved CR and 195 were randomized. The treatment arms did not differ significantly with respect to disease-free survival (DFS; P=0.46) or overall survival (P=0.39). Estimated DFS at 5 years was 32{\%} (95{\%} confidence interval (CI) 23-42{\%}) in the L10M arm and 25{\%} (95{\%} CI 16-33{\%}) in the DAT/MTX/L-asp arm. In each arm, 4{\%} of patients died of toxicities (infection in all but one case). Infections and nausea/vomiting were somewhat more common in the L10M arm (occurring in 68{\%} and 53{\%} of patients respectively) than the DAT/MTX/L-asp arm (56{\%} and 33{\%}). The DAT/MTX/L-asp consolidation regimen was associated with some reduction in nonfatal toxicities, but no significant improvement in DFS, overall survival or non-relapse mortality when compared to the standard L10M regimen.",
keywords = "Acute lymphoblastic leukemia, Consolidation, Randomized",
author = "Petersdorf, {S. H.} and Kopecky, {K. J.} and Head, {D. R.} and Boldt, {D. H.} and Balcerzak, {S. P.} and T. Wun and Vivek Roy and Veith, {R. W.} and Appelbaum, {F. R.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1038/sj.leu.2402006",
language = "English (US)",
volume = "15",
pages = "208--216",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia

T2 - A Southwest Oncology Group study

AU - Petersdorf, S. H.

AU - Kopecky, K. J.

AU - Head, D. R.

AU - Boldt, D. H.

AU - Balcerzak, S. P.

AU - Wun, T.

AU - Roy, Vivek

AU - Veith, R. W.

AU - Appelbaum, F. R.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The effectiveness of intensive post-remission chemotherapy regimens for adult patients with acute lymphoblastic leukemia (ALL) is limited by both a high rate of disease recurrence and a substantial incidence of treatment toxicity. To evaluate a potentially more effective and less toxic approach, we conducted a multicenter phase III trial of consolidation therapies comparing the standard L10M regimen with one combining the brief, intensive L17M regimen and escalating methotrexate (MTX) and L-asparaginase (L-asp). Patients over age 15 with previously untreated ALL were eligible. Induction therapy included vincristine, prednisone, doxorubicin, cyclophosphamide and intrathecal methotrexate administered over 36 days. Patients who achieved complete remission (CR) were randomized to receive consolidation with either the L10M regimen or with DAT (daunomycin, cytosine arabinoside, 6-thioguanine) and escalating MTX and L-asp. The randomization was stratified by age, WBC and Ph chromosome status. Maintenance therapy was the same in both arms. Of 353 eligible patients, 218 (62%) achieved CR and 195 were randomized. The treatment arms did not differ significantly with respect to disease-free survival (DFS; P=0.46) or overall survival (P=0.39). Estimated DFS at 5 years was 32% (95% confidence interval (CI) 23-42%) in the L10M arm and 25% (95% CI 16-33%) in the DAT/MTX/L-asp arm. In each arm, 4% of patients died of toxicities (infection in all but one case). Infections and nausea/vomiting were somewhat more common in the L10M arm (occurring in 68% and 53% of patients respectively) than the DAT/MTX/L-asp arm (56% and 33%). The DAT/MTX/L-asp consolidation regimen was associated with some reduction in nonfatal toxicities, but no significant improvement in DFS, overall survival or non-relapse mortality when compared to the standard L10M regimen.

AB - The effectiveness of intensive post-remission chemotherapy regimens for adult patients with acute lymphoblastic leukemia (ALL) is limited by both a high rate of disease recurrence and a substantial incidence of treatment toxicity. To evaluate a potentially more effective and less toxic approach, we conducted a multicenter phase III trial of consolidation therapies comparing the standard L10M regimen with one combining the brief, intensive L17M regimen and escalating methotrexate (MTX) and L-asparaginase (L-asp). Patients over age 15 with previously untreated ALL were eligible. Induction therapy included vincristine, prednisone, doxorubicin, cyclophosphamide and intrathecal methotrexate administered over 36 days. Patients who achieved complete remission (CR) were randomized to receive consolidation with either the L10M regimen or with DAT (daunomycin, cytosine arabinoside, 6-thioguanine) and escalating MTX and L-asp. The randomization was stratified by age, WBC and Ph chromosome status. Maintenance therapy was the same in both arms. Of 353 eligible patients, 218 (62%) achieved CR and 195 were randomized. The treatment arms did not differ significantly with respect to disease-free survival (DFS; P=0.46) or overall survival (P=0.39). Estimated DFS at 5 years was 32% (95% confidence interval (CI) 23-42%) in the L10M arm and 25% (95% CI 16-33%) in the DAT/MTX/L-asp arm. In each arm, 4% of patients died of toxicities (infection in all but one case). Infections and nausea/vomiting were somewhat more common in the L10M arm (occurring in 68% and 53% of patients respectively) than the DAT/MTX/L-asp arm (56% and 33%). The DAT/MTX/L-asp consolidation regimen was associated with some reduction in nonfatal toxicities, but no significant improvement in DFS, overall survival or non-relapse mortality when compared to the standard L10M regimen.

KW - Acute lymphoblastic leukemia

KW - Consolidation

KW - Randomized

UR - http://www.scopus.com/inward/record.url?scp=0035101768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035101768&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2402006

DO - 10.1038/sj.leu.2402006

M3 - Article

C2 - 11236936

AN - SCOPUS:0035101768

VL - 15

SP - 208

EP - 216

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -